Purdue University — Imatinib Trial for Drug-Resistant Malaria (2023)
Verified$780K
Funder
Recipient
Date
Aug 2023
Data source
Source
Notes
[Human Health and Wellbeing] Open Philanthropy recommended a gift of $780,000 over three years to Purdue University to support a phase IIa/IIb trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Africa. This research will be coordinated by Professor Philip Low, who previously organized a successful phase II trial of imatinib (and an ongoing phase III trial) in Vietnam. This follows our September 2022 support and falls within our focus area of scientific research, specifically within our interest in advancing human health and wellbeing.
Other Grants by Coefficient Giving
2625| Grant | Recipient | Amount | Date |
|---|---|---|---|
| Janaagraha — Air Quality Grants Assessment | $195K | Dec 2024 | |
| Futurewise — Housing Advocacy in Washington | $450K | Apr 2023 | |
| Exscientia — Agonists for Interferon Lambda | $2.3M | Sep 2023 | |
| Kurzgesagt — Short-form Video Content | $3M | Mar 2022 | |
| Kurzgesagt — Video Production (2023) | $1.7M | May 2023 | |
| Kurzgesagt — Video Creation and Translation | $2.6M | Dec 2021 | |
| Lightcone Infrastructure – General Support | Lighthaven (Event Venue) | $4.5M | Sep 2022 |
| Lightcone Infrastructure — General Support (2023) | Lighthaven (Event Venue) | $3M | Oct 2023 |
| Conjecture — Cybersecurity Bootcamp | Conjecture | $223K | Jun 2025 |
| Conjecture — AI Safety Technical Program | Conjecture | $224K | May 2023 |
Showing 10 of 2625 grants